Needham Reiterates Buy on Pacira BioSciences, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Pacira BioSciences (NASDAQ:PCRX) and maintained a price target of $43.
July 02, 2024 | 5:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Pacira BioSciences (NASDAQ:PCRX) and maintained a price target of $43.
The reiteration of a Buy rating and the maintenance of a $43 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100